| Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ... Cancer cell 31 (6), 833-843. e5, 2017 | 503 | 2017 |
| Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC … K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ... The Lancet Haematology 5 (12), e609-e617, 2018 | 220 | 2018 |
| Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma M Roschewski, K Dunleavy, JS Abramson, BL Powell, BK Link, P Patel, ... Journal of clinical oncology 38 (22), 2519-2529, 2020 | 151 | 2020 |
| Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder C Melani, ES Jaffe, WH Wilson Blood, The Journal of the American Society of Hematology 135 (16), 1344-1352, 2020 | 99 | 2020 |
| End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making C Melani, R Advani, M Roschewski, KM Walters, CC Chen, L Baratto, ... Haematologica 103 (8), 1337, 2018 | 85 | 2018 |
| PD-1 blockade in mediastinal gray-zone lymphoma C Melani, A Major, J Schowinsky, M Roschewski, S Pittaluga, ES Jaffe, ... New England Journal of Medicine 377 (1), 89-91, 2017 | 71 | 2017 |
| Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma S Pittaluga, A Nicolae, GW Wright, C Melani, M Roschewski, S Steinberg, ... Blood cancer discovery 1 (2), 155-161, 2020 | 47 | 2020 |
| Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma R Lakhotia, C Melani, K Dunleavy, S Pittaluga, N Saba, L Lindenberg, ... Blood Advances 6 (8), 2667-2680, 2022 | 34 | 2022 |
| Liquid biopsy in non‐Hodgkin's lymphoma C Melani, WH Wilson, M Roschewski Hematological Oncology 37, 70-74, 2019 | 22 | 2019 |
| Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL MD Miljkovic, C Melani, S Pittaluga, R Lakhotia, N Lucas, A Jacob, ... Blood Advances 5 (20), 4198-4210, 2021 | 21 | 2021 |
| Molecular monitoring of cell-free circulating tumor DNA in non-Hodgkin lymphoma. C Melani, M Roschewski Oncology 30 (8), 731-731, 2016 | 21 | 2016 |
| Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-cell lymphoma: safety, efficacy and molecular analysis C Melani, R Lakhotia, S Pittaluga, MD Miljkovic, JD Phelan, JR Muppidi, ... Blood 136, 44-45, 2020 | 20 | 2020 |
| Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R M Roschewski, K Dunleavy, JS Abramson, BK Link, S Parekh, ... Blood 130, 188, 2017 | 19 | 2017 |
| MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R C Lai, M Roschewski, C Melani, S Pittaluga, M Shovlin, SM Steinberg, ... Leukemia & lymphoma 59 (2), 505-508, 2018 | 18 | 2018 |
| Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma C Melani, R Lakhotia, S Pittaluga, JD Phelan, DW Huang, G Wright, ... New England Journal of Medicine 390 (23), 2143-2155, 2024 | 16 | 2024 |
| Risk‐adapted therapy in adults with burkitt lymphoma: updated results of a multicenter prospective phase II study of DA‐EPOCH‐R K Dunleavy, M Roschewski, JS Abramson, B Link, S Parekh, ... Hematological Oncology 35, 133-134, 2017 | 16 | 2017 |
| Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma R Lakhotia, C Melani, S Pittaluga, K Dunleavy, NS Saba, AN Lucas, ... Blood 132 (Supplement 1), 147-147, 2018 | 13 | 2018 |
| Phase 1 study of escalating doses of ibrutinib and temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) with isavuconazole for relapsed and … M Roschewski, C Melani, R Lakhotia, S Pittaluga, JD Phelan, C Peer, ... Blood 136, 12-13, 2020 | 12 | 2020 |
| Dose-adjusted teddi-R induces durable complete remissions in relapsed and refractory primary CNS lymphoma M Roschewski, MS Lionakis, C Melani, JA Butman, S Pittaluga, AN Lucas, ... Blood 132, 4195, 2018 | 12 | 2018 |
| A prospective study of clonal evolution in follicular lymphoma: circulating tumor DNA correlates with overall tumor burden and fluctuates over time without therapy A Distler, R Lakhotia, JD Phelan, S Pittaluga, C Melani, JR Muppidi, ... Blood 138 (Supplement 1), 1328-1328, 2021 | 11 | 2021 |
Wyndham WilsonNational Cancer InstituteVerified email at mail.nih.gov